David Tepper's $2.275 billion deal to buy the Carolina Panthers is expected to close in the next two weeks, drawing to an end the era of team founder Jerry Richardson.
Keep Reading →
June 29 - Hedge Funds, Insider Trading - Comments
William Ackman's private hedge fund has gained more than 9 percent this year while his publicly traded fund is up double digits, marking a dramatic reversal for the billionaire...
Keep Reading →
June 15 - Hedge Funds, Insider Trading - Comments
NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- James Simons, founder and chairman of Renaissance Technologies, took home $1.7 billion in 2017 to claim the No.
Keep Reading →
May 30 - Hedge Funds, Insider Trading - Comments
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities...
Keep Reading →
June 7 - Hedge Funds - Comments
Before we get to the list of 7 over-the-counter diet pills that work without exercise, we should ask ourselves if there exists such a thing. The short answer is no.
Keep Reading →
April 12 - Lists, News - Comments
Are you interested in knowing the 7 Most Popular Diet Pills That Work Fast Without Exercise? I mean what better way to lose weight than to simply pop some pills and let the fat...
Keep Reading →
March 15 - Lists, News - Comments
Daniel Gold, the manager of QVT Financial, is bullish on CytRx Corporation (NASDAQ:CYTR).
Keep Reading →
March 24 - Hedge Funds, News - Comments
According to a new filing with the Securities and Exchange Commission, Daniel Gold’s fund, QVT Financial, boosted its stake in China Zenix Auto International Ltd (NYSE:ZX), ...
Keep Reading →
March 12 - Hedge Funds, News - Comments
Alex Denner’s Sarissa Capital disclosed its holdings in its latest and first 13F filings.
Keep Reading →
February 14 - Hedge Funds, News - Comments
It's really amazing to think about how far we've come over even the past decade in the health-care arena.
Keep Reading →
September 23 - News - Comments
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued a press release pointing out that its marketing partner Eisai had started direct-to-consumer advertising for their obesity drug...
Keep Reading →
September 17 - News - Comments
Heart disease is the leading cause of death in the United States. In 2010, according to data from the Centers for Disease Control and Prevention, 597,689 people in the U.S.
Keep Reading →
September 16 - News - Comments
Let's start with CONN'S, Inc. (NASDAQ:CONN). The retailer of consumer electronics, appliances, and furniture slumped after missing estimates.
Keep Reading →
September 9 - News - Comments
College football arrived in a big way over the past week or so, with plenty of big plays already.
Keep Reading →
September 7 - News - Comments
The first guy, Leland Wilson, got kicked out. Never mind that he founded the company, Samuel Colin, senior managing partner at First Manhattan, VIVUS, Inc.
Keep Reading →
September 5 - News - Comments
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Keep Reading →
September 3 - News - Comments
As much as I think Arena Pharmaceuticals, Inc.
Keep Reading →
September 3 - News - Comments
You really don't need both. There are enough people with rheumatoid arthritis or high cholesterol, for example, to have multiple blockbuster drugs that treat the diseases.
Keep Reading →
September 3 - News - Comments
This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Keep Reading →
August 30 - News - Comments
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Keep Reading →
August 30 - News - Comments
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Keep Reading →
August 30 - News - Comments
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s Belviq, VIVUS, Inc. (NASDAQ:VVUS)'s Qsymia, and Orexigen Therapeutics, Inc. (NASDAQ:OREX)'s Contrave were rejected by the Food and...
Keep Reading →
August 29 - News - Comments
Obesity has become a central issue in the global health care agenda; both governments and their citizens are becoming increasingly more conscious about this problem, which is ...
Keep Reading →
August 28 - News - Comments
The obesity segment of the health care industry is turning into a battleground. VIVUS, Inc.
Keep Reading →
August 23 - News - Comments
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Keep Reading →
August 22 - News - Comments
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market.
Keep Reading →
August 22 - News - Comments
MannKind Corporation (NASDAQ:MNKD) has gotten one of the biggest votes of confidence we've seen from the smart money, out of the entire stock market universe and the 500+ elite...
Keep Reading →
August 22 - News - Comments
The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database.
Keep Reading →
August 19 - News - Comments
After my article on MannKind Corporation (NASDAQ:MNKD) earlier this week, a reader wasn't too happy about my view that the company was overvalued given the most recent phase ...
Keep Reading →
August 19 - News - Comments
Last week, the Trust for America's Health and the Robert Wood Johnson Foundation released their annual report (link opens a PDF to a 116-page report) on obesity trends in the ...
Keep Reading →
August 19 - News - Comments
We are a nation that is completely and utterly devoted to the convenience of fast food.
Keep Reading →
August 15 - News - Comments
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Keep Reading →
August 13 - News - Comments
Quite a few research papers published recently have shown that mutations in genes can control your appetite and your ability to burn calories.
Keep Reading →
August 11 - News - Comments
We are a nation that is completely and utterly devoted to the convenience of fast food.
Keep Reading →
August 11 - News - Comments
The sales come from less than a month on the market -- the drug launched on June 11 and the quarter closed on June 30 -- and can't tell you anything about the long-term potential...
Keep Reading →
August 2 - News - Comments
Arena Pharmaceuticals, Inc.
Keep Reading →
July 31 - News - Comments
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
Keep Reading →
July 30 - News - Comments
The two weight-loss drug approvals in 2012 were the first in more than a decade. The excitement surrounding Arena Pharmaceuticals, Inc.
Keep Reading →
July 28 - News - Comments
The most comprehensive look at hedge fund activity comes in the form of quarterly 13F filings, which disclose many of a fund’s positions as of the end of the quarter.
Keep Reading →
July 19 - Hedge Funds - Comments
"As a founding CEO, over the past 22 years, Leland has secured four drug approvals, an unheard-of achievement for a small pharmaceutical company. He has taken VIVUS, Inc.
Keep Reading →
July 19 - News - Comments
On Saturday, VIVUS, Inc.
Keep Reading →
July 17 - News - Comments
For a long time, VIVUS, Inc. (NASDAQ:VVUS) was operating as the only player in the anti-obesity market. However, the entry by Arena Pharmaceuticals, Inc.
Keep Reading →
July 16 - News - Comments
With all of the factors we have to worry about in our everyday lives, it is somewhat a wonder that we're not only able to survive, but thrive, as a society.
Keep Reading →
July 15 - News - Comments
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Keep Reading →
July 15 - News - Comments
VIVUS, Inc. (NASDAQ:VVUS) has found an Italian to help it out.
Keep Reading →
July 10 - News - Comments
After more than a year, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’ weight-loss drug Belviq has finally launched.
Keep Reading →
July 9 - News - Comments
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
Keep Reading →
July 3 - News - Comments
